SCHEDULE 13G/A: Bleichroeder LP and Affiliates Disclose 9.99% Stake in Evoke Pharma, Inc.

Bleichroeder LP, along with Bleichroeder Holdings LLC and Andrew Gundlach, has filed an amended Schedule 13G disclosing a 9.99% beneficial ownership stake in Evoke Pharma, Inc., primarily held through The Denise and Michael Kellen Foundation.

Summary

• Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach collectively reported beneficial ownership of 849,367 common shares of Evoke Pharma, Inc.
• This represents 9.99% of the outstanding common shares of Evoke Pharma, Inc.
• The reported shares include 825,000 shares of common stock and 24,367 shares issuable upon the exercise of warrants.
• The holdings are primarily through The Denise and Michael Kellen Foundation, a charitable foundation for which Bleichroeder LP acts as an investment adviser.
• The exercise of warrants is subject to a beneficial ownership limitation of 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon exercise.
• Without this limitation, the reporting persons would beneficially own 5,882,352 shares, representing 43.46% of the outstanding common stock, including 5,057,352 shares from warrants.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Evoke Pharma, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without explicit positive or negative performance indicators. The significant stake could be viewed positively by some, but the warrant limitation introduces a neutral element.

Positives

• A significant beneficial ownership stake of 9.99% by Bleichroeder LP and its affiliates indicates a notable investment and potential confidence in Evoke Pharma, Inc.
• The disclosure clarifies that the investment is for ordinary course of business, not for control, which can reduce concerns about activist intentions.

Negatives

• The beneficial ownership limitation of 9.99% on warrant exercise prevents the reporting persons from immediately converting a substantial portion of their potential ownership (up to 43.46%) into common shares, limiting their immediate influence or liquidity.

Risks

• The beneficial ownership limitation on warrants restricts the immediate conversion of a significant number of potential shares (5,057,352 shares) into common stock, which could impact the reporting persons' ability to fully realize their investment or exert greater influence if desired.

Future Outlook

NA

Industry Context

This filing reflects an investment firm's strategic stake in a pharmaceutical company, a common practice in the investment landscape where specialized funds or advisors identify opportunities within specific sectors. The nature of the investment, particularly the warrant holdings, suggests a long-term interest, potentially tied to the company's future product development or market performance within the pharmaceutical industry.

Related Party Transactions

• The Denise and Michael Kellen Foundation, a charitable foundation for which Bleichroeder LP acts as investment adviser, holds the shares and warrants reported.

Stakeholder Impact

• Shareholders may view the significant stake by Bleichroeder LP and its affiliates as a vote of confidence in Evoke Pharma, Inc.'s future prospects.
• The disclosure of a substantial potential ownership (43.46% without limitation) could influence market perception regarding the company's control structure, even if the current beneficial ownership is capped at 9.99%.

Key Dates

Keywords

Evoke Pharma Inc., Bleichroeder LP, Schedule 13G, Beneficial Ownership, Common Shares, Warrants, Investment Adviser, SEC Filing, Ownership Disclosure, Pharmaceuticals